Alterity Therapeutics Showcases Innovative Research at Global Conference
– Data from ATH434-201 double-blind Phase 2 trial to be featured in oral session and multiple poster presentations –
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a leading biotechnology company committed to developing disease-modifying treatments for neurodegenerative diseases, has made exciting announcements regarding the ATH434-201 randomized, double-blind Phase 2 clinical trial focused on Multiple System Atrophy (MSA). This groundbreaking research will be presented at the International Congress of Parkinson’s Disease and Movement Disorders (MDS), which is set to take place from October 5-9 in a picturesque location.
Highlighting Key Findings
David Stamler, M.D., the Chief Executive Officer of Alterity, expressed enthusiasm about sharing the trial's findings with the movement disorders community. "We anticipate sharing valuable insights into ATH434 as a pioneering treatment for MSA," he commented. The research underscores the urgency for effective therapies in a landscape where traditional options fall short.
Details of the Presentations
Alterity will feature several presentations at MDS 2025, including an oral platform presentation and two posters. The oral presentation titled “ATH434 Slowed Disease Progression in a Phase 2 Study in Multiple System Atrophy” will be held on October 8, 2025. Dr. Stamler will take the stage, sharing vital data and insights that could shape the future of MSA treatments.
Poster Presentations
Following the oral session, the research team will present:
- Relationship Between Alpha-Synuclein Aggregation Profiles, Imaging Biomarkers, and Disease Severity in a Phase 2 Study of ATH434 in MSA, presented by Margaret Bradbury, Ph.D., on October 5.
- Differences Between Clinical and Imaging Phenotypes in Phase 2 Study of ATH434 in Multiple System Atrophy, presented by Paula Trujillo, PhD, also on October 5.
Both presentations aim to delve deeper into the effectiveness and implications of ATH434 on patients suffering from this debilitating condition.
Understanding ATH434
ATH434 represents a significant advancement in the therapeutic approach to neurodegenerative diseases. Specifically designed as an oral agent, it works by inhibiting the aggregation of pathological proteins that are known contributors to neurodegeneration. Impressively, preclinical studies have shown that ATH434 reduces ?-synuclein pathology while restoring normal iron balance in the brain, fostering neuronal survival and performance.
Early Phase 1 trials demonstrated that ATH434 is well tolerated, with brain concentrations that correspond to levels previously validated in animal models as effective. The promising outcomes from initial trials indicate substantial clinical efficacy and safety, laying the groundwork for future developments in MSA treatment.
Phase 2 Clinical Trial Insights
The ATH434-201 Phase 2 trial was meticulously structured as a randomized, double-blind, placebo-controlled study. Participants, totaling 77 adults, were monitored over 12 months, during which they received either ATH434 at different doses or a matching placebo. Significant findings emerged, highlighting clinically meaningful improvements on several scales that measure the impact of MSA.
Notably, measures such as the modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I revealed substantial benefits associated with ATH434, particularly in terms of daily living activities. Other evaluations, including motor performance assessments, aligned with these positive outcomes, reinforcing the agent’s potential.
The Challenge of Multiple System Atrophy
Multiple System Atrophy (MSA) is a tragic and rare neurodegenerative disorder, unmistakable for its adverse impact on movement and involuntary bodily functions. As the disorder progresses, it diminishes the quality of life and profoundly affects daily activities. Strikingly, MSA results from the progressive loss of critical nerve cells in various brain regions, leading to a spectrum of debilitating symptoms, including movement difficulties and autonomic dysfunction.
Currently, MSA affects approximately 50,000 individuals in the U.S. Unfortunately, available medications offer little more than symptomatic relief and do not address the core issue of disease progression.
Alterity Therapeutics: Pioneering Future Solutions
Alterity Therapeutics is dedicated to revolutionizing therapeutic options for neurodegenerative diseases. Through the ongoing development of ATH434 and a robust drug discovery platform, the company aims to address the underlying pathologies that contribute to the progression of conditions like Parkinson’s Disease and MSA.
With a base in both Melbourne and San Francisco, the company's commitment to exploring innovative treatments is evident in its ongoing trials and research initiatives, which continue to generate critical data shedding light on the potential of ATH434.
Company Contacts
To learn more about Alterity Therapeutics, you can visit their official website. For investor inquiries, reach out to Remy Bernarda at ir@alteritytx.com or call +1 (415) 203-6386. For media inquiries, contact Casey McDonald at cmcdonald@tiberend.com or call +1 (646) 577-8520.
Frequently Asked Questions
What is the focus of the ATH434-201 trial?
The trial aims to assess the effectiveness and safety of ATH434 in patients with Multiple System Atrophy over a 12-month period.
When will the presentations take place?
Presentations will occur from October 5-9 at the International Congress of Parkinson's Disease and Movement Disorders.
Who will be presenting the oral presentation?
David Stamler, M.D., the CEO of Alterity, will present the oral findings on October 8, 2025.
What are the possible benefits of ATH434?
ATH434 has shown potential in slowing disease progression, improving daily living activities, and reducing neuronal damage associated with MSA.
Is there a cure for Multiple System Atrophy?
Currently, there is no cure for MSA, but therapies like ATH434 may offer hope in slowing disease progression and improving quality of life.
